Cellectis (CLSS) Confirms IPO Filing for Calyxt

Cellectis S.A. (Nasdaq : CLLS) and Calyxt, Inc. announced that Calyxt has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of shares of Calyxt common stock. Calyxt is Cellectis’ 100% owned gene editing agriculture company. The number of shares to be offered and the price range for the offering have not yet been determined, although Cellectis intends to retain majority ownership of Calyxt.

Citigroup, Credit Suisse and Jefferies are acting as joint book-running managers for the proposed offering. Wells Fargo Securities is acting as lead manager and Ladenburg Thalmann is acting as co-manager.

You May Also Be Interested In

• UiPath names new CFO and adds board member amid leadership reshuffle
• Blue Owl Technology Finance closes $150M senior unsecured notes
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks